Notwithstanding the fact that streptomycetes are overlooked in clinical laboratories, studies describing their occurrence in disease and potential pathogenicity are emerging. Information on their species diversity in clinical specimens, aetiology and appropriate therapeutic treatment is scarce. We identified and evaluated the antibiotic susceptibility profile of 84 Streptomyces clinical isolates from the Czech Republic. In the absence of appropriate disk diffusion (DD) breakpoints for antibiotic susceptibility testing (AST) of Streptomyces spp., we determined DD breakpoints by correlation with the broth microdilution method and by the distribution of zone diameters among isolates. Correlation accuracy was high for 9 antibiotics, leading to the establishment of the most valid DD breakpoints for Streptomyces antibiotic susceptibility evaluation so far. Clinical strains belonged to 17 different phylotypes dominated by a cluster of strains sharing the same percentage of 16S rRNA gene sequence identity with more than one species (S. albidoflavus group, S. hydrogenans, S. resistomycificus, S. griseochromogenes; 70% of isolates). AST results showed that Streptomyces exhibited intrinsic resistance to penicillin, general susceptibility to amikacin, gentamycin, vancomycin and linezolid, and high percentage of susceptibility to tetracyclines and clarithromycin. For the remaining antibiotics, AST showed inter- and intra-species variations when compared to available literature (erythromycin, trimethoprim-sulfamethoxazole), indicating a region-dependent rather than species-specific patterns.
Despite the great contribution of Streptomyces to medicine as a source of many bioactive compounds (antibiotics, immunosuppressants, antifungals and antivirals), they also have a potentially dark side and can cause infections in humans. The most common infection caused by Streptomyces is actinomycetoma, an endemic disease associated with S. somaliensis, S. sudanensis, S. griseus and S. viridis1,2,3,4,5. In addition to mycetoma, Streptomyces can also cause rare invasive infections such as pulmonary infections, bacteremias, brain abscesses, peritonitis and other diseases, mainly in immunocompromised patients (reviewed in6,7). New approaches using next generation sequencing have recently shown that Streptomyces are likely a common part of the human8,9,10,11. However, the role of clinical Streptomyces isolates of unknown aetiology reported in numerous studies12,13,14 remains unclear. Indeed, many Streptomyces secondary metabolites exhibit harsh effects in vitro (strong cytotoxic and β-hemolytic activities) and can play a significant role in the human immune response6. Moreover, examination of the genome of Streptomyces sp. TR1341 isolated from the sputum of an elderly patient with a long history of respiratory problems revealed the presence of several genes for opportunistic colonization of human tissues and for the resistance to antibiotics15. Their significance as opportunistic pathogens, the presence and description of possible virulence factors, and antibiotic susceptibility in the context of antibiotic resistance determinant transmission remain to be investigated.
The tendency to isolate streptomycetes from clinical specimens has increased in the last decade1,6,7,14,16,17,18,19. This may be due to increasing air pollution in industrial and agricultural areas (dust as a vector for Streptomyces spores), but also to a growing number of immunodeficient patients caused by extrinsic/external factors (e. g. HIV infection, immunosuppressive drugs, environmental toxins or malnutrition)20. Nevertheless, streptomycetes are still neglected in clinical practice, due to a lack of awareness of their clinical relevance and probably due to difficulties associated with their growth characteristics, which complicates their isolation in clinical laboratories. Streptomyces are usually slow-growing bacteria that are rapidly overgrown by common respiratory microbiota during routine cultivations. To eliminate the fast-growing bacteria, some mycobacteriological laboratories decontaminate clinical specimens with N-Acetyl-L-Cysteine-Sodium Hydroxide (NALC-NaOH). However, the negative effects of NALC-NaOH on the recovery of mycobacteria and Nocardia spp. have been reported21,22,23. Reduction of Streptomyces population and species selection cannot be ruled out. Even if Streptomyces survive this crude decontamination step, they will most likely be considered as contaminants, since microscopic identification requires an experienced person24.
Because of the limited number of studies reporting antibiotic susceptibility profiles of clinical Streptomyces, with respect to the total of 674 Streptomyces species names validly published25, antibiotic therapy against such infections is at best questionable. There is a consistent agreement that clinical Streptomyces isolates are susceptible to amikacin, gentamycin, vancomycin, and linezolid. In contrast, the vast majority of clinical isolates tested to date have been resistant to penicillin, the oldest known antibiotic. For the remaining antibiotics, there are differences in susceptibility patterns between species3,5,13,14,16,26,27,28,29,30,31,32,33,34. The results available in the literature suggest species-specific susceptibility, but the number of species-identified clinical isolates is too small to draw a clear conclusion.
The key to predicting the clinical success or failure of a therapy is the antibiotic susceptibility test (AST), i.e., the in vitro response of the pathogen to selected antibiotics. The interpretive criteria to categorize an organism as susceptible (S), intermediate (I) or resistant (R)35 are clinical breakpoints. In addition to clinical breakpoints that guide therapy, the concept of epidemiological cut-off values (ECOFF) has been also defined. The ECOFF value serves as threshold for detecting bacteria with resistance mechanisms and for monitoring the evolution of resistance among isolates of the same bacterial species. This value divides a given bacterial population into a wild type group and a group with acquired or mutational resistance to a given drug36.
The golden standard in AST is the broth microdilution method (BM). As a fast alternative with a lower cost serves disk diffusion method (DD). Since Streptomyces spp. are better adapted to growth on solid/semi-solid media37, DD method is more suitable for Streptomyces AST. While the DD method has been reported mainly in the characterization of environmental Streptomyces38,39,40, its use in clinical setting is not excluded19. However, given the lack of breakpoints for Streptomyces AST, the results of studies using DD method could be difficult to interpret or even misleading, increasing the likelihood of treatment failure.
The objectives of the present study were: i) to perform a taxonomic classification based on the 16S rRNA gene of 84 clinical isolates of Streptomyces collected in Czech Republic, ii) to determine their antibiotic susceptibility profile using the DD method, iii) to evaluate the presence of acquired resistance mechanisms; and iv) to review antibiograms of clinical Streptomyces strains available in literature to discuss the suitability of the antibiotic therapy. Since the clinical breakpoints for the evaluation of the DD method results in Streptomyces or related organisms are not defined by an official scientific body, we attempted, for the first time, to correlate the DD results with the results of the broth microdilution (BM) techniques standardized by the Clinical and Laboratory Standard Institute (CLSI) for Streptomyces related organisms and to set appropriate DD breakpoints for antibiotic profiling of Streptomyces spp.
Materials and methods
Bacterial isolates acquisition and identification
The study included 84 non-duplicated human clinical isolates collected between 2009 and 2018 at the Trutnov Regional Hospital (29 strains, strain coding TR), the Ostrava Public Healthcare Institute (53 strains, strain coding OS), and the Příbram Regional Hospital (2 strains, strain coding PR). All strains were isolated during routine diagnostics in mycobacteriology laboratories. Strains have been deposited in the Collection of Actinomycetes of the Biology Centre Collection of Organisms (BCCO, www.actinomycetes.bcco.cz). DNA extraction and identification of all isolates was performed according to41. The 16S rRNA gene sequences were compared against the type strains database using the Basic Local Alignment Search Tool42. The phylogenetic tree was constructed using Geneious (v 8.1.6, http://www.geneious.com, neighbour joining, Tamura-Nei genetic distance model, 1000 replicates). The strains were assigned to different clades according to43. The list of all strains and the reference strains most closely related according to 16S rRNA gene similarity and their classification into clusters are reported in Table 1. Strain TR1341 (here assigned to S. murinus based on nucleotide similarity of the 16S rRNA gene) was discussed in the previous study6. The nucleotide sequences of the 16S rRNA genes of the isolates were deposited in GenBank under the accession numbers MZ393577-MZ393782 (Supplementary Table S1).
Antibiotic susceptibility testing
The antimicrobials used in the study are listed in Table 2. The abbreviations and disk contents are included.
Disk diffusion test
Strains were grown on ISP3 medium44 prior AST at 36 °C (28 °C for soil isolates). The 0.5 McFarland suspension was prepared as described by CLSI in the M24 manual45. A total of 200 µL of suspension was spread on Mueller–Hinton agar 90-mm plates (Dulab, Dubné, Czech Republic). Commercial antibiotic disks (Bio-Rad, Hercules, CA, USA) were used. Plates were incubated at 36 °C. Zones were measured after 24 or 48 h, depending on the growth rate of the strain. In the case of trimethoprim-sulfamethoxazole, slight growth within the zone was ignored as recommended in guidelines for broth microdilution method45.
Clinical breakpoints setting
To develop a criterion for interpreting DD results, we followed three different approaches. (1) To correlate DD with BM results for antibiotics available in a commercial BM kit. The minimum inhibitory concentration (MIC) breakpoints chosen to the derive zone diameter (ZD) breakpoints are reported in Table 2. We selected 29 clinical isolates and the number of strains belonging to a given cluster was selected proportionately. To increase the robustness of the correlation analysis, 18 additional soil Streptomyces isolates (also deposited in BCCO) and the type strains S. rameus DSM 41685 and S. violaceoruber DSM 40783 were included in the study. The soil and type strains were subjected to the same procedures as the clinical isolates, except for the growth temperature, which was set to 28 °C. The soil isolates belonged to the same clusters as the clinical ones when possible. A total of 49 Streptomyces strains were used in the correlation analysis (Table 1). (2) For antibiotics not available in a commercial BM kit, we proposed at least tentative breakpoints based on the distribution of the ZD data and the class of the antibiotic. (3) For antibiotics not available in a commercial BM kit and without a clear cut-off in the distribution of ZDs, we used arbitrary ZD breakpoints.
Minimum inhibitory concentration (MIC) determinations
The BM method for aerobic Actinomycetes described by CLSI in the M24 manual45 was performed according to the guidelines. The commercial BM kits MIKROLATEST MIC® (Erba Lachema, Brno, Czech Republic) with dried antibiotics were used to determine MICs. Results were read after 72 h (optimal growth of all strains). The strains Enterococcus faecalis DSM 2570 and Escherichia coli DSM 1103 were used as quality control as recommended in BM kits guidelines.
Binary logarithms of the MIC values (mg/L) and average ZDs (mm) were calculated. Correlation between log MIC and average ZDs was tested using the Pearson correlation coefficient. The accuracy limit was set at r > 0.75. Off-scale values were excluded. ZD interpretive susceptibility criteria were derived from the scattergrams of MIC endpoints and the ZD values followed by the error rate-bounded method46. The discrepancy percentage between the correlated methods was calculated as very major error (VM; false-susceptible by disk diffusion), major error (M; false-resistant by disk diffusion) and minor error (m; one of the test results is intermediate and the other is susceptible or resistant). Epidemiological cut-off values (COWT) to distinguish wild type and non-wild type populations (group with acquired or mutational resistance to that drug) were determined by automatic calculation for the zone distributions using the Normalized Resistance Interpretation47 method for most the abundant species only. The obtained frequencies of resistant phenotypes were compared with those reported in a recent study14 of clinical isolates from Spain. The concordance between resistance profiles for overlapping antibiotics was evaluated by Pearson´s chi-squared test (α = 0.01). Only antibiotics with available MIC-DD correlation were included in the comparison (CIP, ERY and SXT). The frequency of resistance to the tested antibiotics, except those with arbitrary breakpoints (SMN, RIF and OFX), was calculated to determine multidrug resistance patterns of the clinical isolates.
Review on available antibiograms
Since the studies from clinical disciplines are presumed to use standardized methods for AST evaluation, we focused only on antibiograms reported for clinical Streptomyces. If MIC or ZD values were stated in studies3,12,19,32,48, we evaluated the susceptibility profile using the breakpoints cited or derived in our study.
For more details about Material and Methods see Supplementary Text S1.
The selected 84 clinical Streptomyces strains belong to 16 different phylotypes (Table 1). Most strains (83%) have the same percentage of sequence identity (PID) with more than one Streptomyces species due to insufficient variation in their 16S rRNA gene sequence (all clinical strains PID > 99%, except OS587 with PID 98.88%). The phylogenetic tree of the clinical Streptomyces strains was complemented with environmental and type strains (Fig. 1). The clinical strains were then assigned to 13 phylogenetic clusters, with cluster C (S. albidoflavus group/S. hydrogenans/S. resistomycificus/S. griseochromogenes) comprising 70% of all clinical isolates.
ZD breakpoints setting
To derive ZD interpretive criterion, 3 different approaches were followed: i) Correlation of BM MICs values with zone diameters when antibiotics available in commercial BM kits; ii) Tentative breakpoints setting based on the distribution of ZD data and class of the antibiotic for antibiotics without correlation analysis; iii) Arbitrary ZD breakpoints when the distribution of ZDs did not reveal a clear cut-off for S-R category for antibiotics without correlation analysis.
Correlation analysis-based breakpoints
We found a strong negative correlation (Pearson´s correlation r ˂ −0.89) between MIC and ZD values for AMP, ERY, TET, CMP, CIP, and PEN (−0.96, −0.94, −0.93, −0.90, −0.89 and −0.75, respectively). The proposed ZD breakpoints and the COWT values are shown in Table 2. Discrepancy percentages of proposed breakpoints were in acceptable ranges. Scattergrams and discrepancy percentages are shown in Fig. 2 and Supplementary Figures S1–S7. Evaluation of the correlation between MIC and ZD values for SXT was problematic due to difficulties in determining the MIC and ZD endpoints, which is likely reflected in a weak correlation (Pearson´s r = −0.60, n = 36, data not shown). In addition, strong disagreement between categories occurred in 27% of strains. This was partially resolved by prolonging the incubation in the DD method to 48 h. However, unsolved inconsistency persisted for cluster D strains (r = −0.87 when cluster D strains were excluded). Incomplete interpretive breakpoints were proposed for VAN, GEN, and AKN, since only susceptible populations were available. Therefore, as ZD susceptibility breakpoints were chosen the minimum ZD values measured while susceptible by BM method.
Breakpoints based on ZD data distribution and on antibiotic class
The ZD distribution of CZN, CRO and CLR allowed us to visually define the R-S cut-offs, as most of the tested clinical Streptomyces strains were indisputably resistant (ZD 7–20 mm) or susceptible (ZD more than 27 mm). The antibiotic class membership and similarity of MIC breakpoint values for unrelated genera (available in the AST guidelines) were considered for MNO, DOX, AMX and AMC (Supplementary Figures S8 and S9).
Arbitrary ZD breakpoints
The ZD distribution of DOX, OFX and SMN did not allow us to visually define the R-S cut-offs, and with the lack of MIC–ZD correlation analysis, we arbitrarily defined the ZD breakpoint values as R ≤ 20 mm, I = 21–29 mm, S ≥ 30 mm (Supplementary Figure S10A-C).
Antibiotic susceptibility testing of clinical Streptomyces isolates
The percentages of resistant, intermediate susceptible and susceptible strains are shown in Table 2. The COWT values defining the cut-offs for the wild type and non-wild type population of the strains in cluster C are also shown in Table 2. The resistance patterns of each Streptomyces phylotype and the assignment of the corresponding graphs are summarized in Table 3.
A high percentage of resistant clinical strains was found in case of penicillin group antibiotics: PEN (100%), AMP (82%) and AMX (81%). The enrichment of AMX with clavulanic acid rapidly decreased the resistance of clinical isolates to 7%. A high resistance frequency was also found in case of CZN, CRO, ERY and SXT: 98%, 88%, 87% and 79%, respectively. In contrast, all clinical isolates were susceptible to AKN, GEN and VAN. A high frequency of susceptible clinical strains was found in case of tetracycline group antibiotics (MNO, DOX, TET), CLR, CMP and CIP: 94–91%, 89%, 85% and 49% (plus 45% in “I” category), respectively. A high frequency of susceptible or intermediate susceptible clinical strains was also found for RIF (62% and 27% as “S” and “I” category) and OFX (7% and 76% as S and I category). However, due to the lack of reliable breakpoints (ZD breakpoints were set arbitrarily) these results need further validation. Within the tested cluster C strains, 3.4%, 3.4%, 6.7%, 8.5%, 1.7% and 1.7% were non-wild type in case of AMX, CZN, CIP, TET, DOX and VAN, respectively. For AKN and RIF, non-wild type populations were not determined, as the cluster C zone diameter datasets have an abnormal distribution. For the remaining tested antibiotics, all strains were wild types.
For AMS and LIZ, we performed only the BM method and only 29 clinical isolates were included. All isolates were susceptible to LIZ. In case of AMS, the MIC values of 83% of tested clinical isolates decreased by 1 or more dilutions compared to the MIC value of AMP alone, i.e., the susceptibility of the strains increased (24% of clinical isolates changed susceptibility category from R to S).
Most isolates were resistant to 7 drugs (53 isolates), with a minimum resistance to 1 drug (TR1144 resistant only to PEN) and with maximum multi-drug resistance to 12 drugs occurring in 2 isolates in cluster B (OS282 and OS1126B) and strain TR1341 of cluster G (Supplementary Figure S11).
The comparison of AST results between clinical isolates of the same cluster (cluster C) collected in Spanish provinces (25 isolates)14 and those in our study (59 isolates) is shown on Fig. 3. The proportion of resistant isolates significantly differs by country for ERY (X2 = 42.314; p ˂ 0.01) and SXT (X2 = 23.789; p ˂ 0.01). The frequency of resistant isolates is 93% and 100% in Czech Republic compared to 24% and 64% in Spain, respectively. The proportion of resistant isolates does not differ for CIP (X2 = 0.401; p = 0.818).
Review on antibiograms
Antibiograms of clinical Streptomyces available in the literature are summarized in Supplementary Table S2 (December 2021). We confirmed general susceptibility to AKN, GEN, VAN and LIZ, and resistance to PEN. For the remaining antibiotics, there are inter- and intra-species variations with unexplained drivers.
Although Streptomyces is increasingly emerging in clinical settings, there is little information on the aetiology, species distribution and antibiotic susceptibility profiles, with respect to the high number of Streptomyces species described to date. These are mostly case reports5,19,28,29,30,32,33,34,49,50,51, with only scarce works addressing the large cohorts of clinical isolates12,13,14. Together with these, our work brings a new perspective on the presence and diversity of Streptomyces spp. in human microbiome, and points, that streptomycetes are important in clinical samples and should receive greater attention.
Here we present identification and AST of 84 clinical Streptomyces isolates collected in Central Europe (Czech Republic). For the first time, we performed a correlation between the BM and DD method in AST of Streptomyces. Most of the strains in our study were isolated from patients suffering from chronic respiratory disease (59.5%), although it is not clear whether they were the cause of the disease, represented a secondary bacterial infection, or they were common colonizers of the human body. Although 17 different phylotypes were identified among the clinical Streptomyces in our study, only 3 of them have been reported as causative organisms of human diseases before: S. albus and S. thermoviolaceus in pulmonary infections27,50,52, S. albus as a causative agent of mycetoma33 and S. thermocarboxydus in keratitis53. A recent study14 identified 6 other phylotypes identical to those presented in our study (S. albidoflavus, S. rutgersensis, S. rochei, S. drozdowiczii, S. xylanilyticus and S. carpaticus), but their clinical relevance is unknown. The phylotypes reported in our study as clusters H, I, L, M, and S. ginkgonis, with S. xiamenensis of cluster A are associated with clinical specimens for the first time. It is interesting to note that cluster C, which is the most abundant in our study (70.2% of clinical isolates), has been reported only in another study so far, and moreover with much less proportion (~ 13% of clinical isolates)14. This could be due to regional differences in agriculture, industry and lifestyle, that could play a role in the colonization of humans by different Streptomyces species, as well as due to complicated taxonomic issues. Taxonomy of Streptomyces species is a complex task involving the identification of genotypic and phenotypic characters54. The sequences in the GenBank database are updated literally every minute, and therefore the reports on species identified decades ago are questionable (e. g. 28 Streptomyces isolates of S. griseus12) and thus difficult to compare.
To evaluate the AST of Streptomyces spp. we chose the modified Kirby-Bauer method correlated with broth microdilution method (CLSI guidelines for Nocardia and other aerobic actinomycetes45) for 10 antibiotics. Since establishing clinical breakpoints is a challenging task, all available MIC breakpoints for Streptomyces spp. were selected as alternatives based on their taxonomic classification. If official MIC breakpoints for Streptomyces spp. are established by an international committee, the DD breakpoints proposed in this study can be easily adjusted using the scattergrams provided.
The correlations were excellent for all tested antibiotics (Pearson´s correlation coefficient ranged from −0.89 to −0.96), except for PEN and SXT. Streptomyces species are known for their benzylpenicillin resistance55, thus all the strongly resistant values outside the MIC range (> 8 mg/L) had to be excluded from the correlation calculation (28 strains). This might have led to less accurate results. In case of SXT, the inconsistency in reading the MIC endpoint occurred. Due to the uneven growth of streptomycetes in liquid cultures (growth in clumps), it is difficult to detect wells with partial growth (20% lower detection rate comparing to control well as recommended by CLSI) or determine a clear cut-off, while slight growth is neglected. Moreover, the unresolved disagreement between methods occurred in cluster D (S. gougerotii). Although SXT is recommended worldwide for the treatment of actinomycetoma56 as an empirical antibiotic therapy, we believe that the treatment of Streptomyces infections with SXT is probably inappropriate because of the low accuracy of the results as well as the high percentage of resistant strains in our study.
The variability of the species in our study is limited and is mainly represented by cluster C strains (70.2%), which have the same or very similar resistance patterns. Considering the species-specific susceptibility profile of Streptomyces57, the notably high percentages of resistance to some antibiotics (AMP, SXT and ERY) may be biased by the large proportion of one phylotype in our data set. Therefore, we compared AST profiles from our study with those for clinical species previously published (Supplementary Table S2). Our data confirmed a general susceptibility of Streptomyces to AKN, GEN, VAN and LIZ. The only discrepancy found in the literature is a strain of S. griseus resistant to AKN with MIC of 16 mg/L12 described as susceptible in the study, but resistant according to current guidelines45. However, the result is questionable, since the AST procedures as well as the methods for identification have changed since the study was published (1990). These antibiotics are associated with the treatment of complicated multi-drug resistant infections and are often reserved as drugs of last resort, some of which have significant side effects58,59,60,61,62. On the contrary, there is intrinsic resistance to PEN, usually recommended as first-line therapy for the treatment of respiratory diseases and pneumonia63. For the remaining antibiotics, there is a considerable variability in the susceptibility profiles of Streptomyces spp., for some of them with high percentage of resistance (cephalosporins, CIP, ERY) or susceptibility (CLR, tetracyclines, imipenem). Thus, if antibiotic other than the safe one must be used, AST of the causative organism is recommended as well as species identification.
The most interesting property of Streptomyces is their ability to produce antibiotics. Since antibiotic resistance genes are thought to originate from antibiotic-producing bacteria, the likelihood of multi-drug resistance (MDR) occurrence is high. For example, there are more than 100 drug resistance gene homologues in the chromosome of Streptomyces coelicolor A3(2)64 and the presence of the Van cluster (vanSRJKHAX) associated with inducible resistance to vancomycin has been reported, too65. Nevertheless, there are indications that most of the MDR systems are suppressed under laboratory conditions and Streptomyces species are therefore generally considered to be drug sensitive66. In our study, we found strains with a wide range of resistance patterns, from generally susceptible to MDR strains. It is noteworthy that one of the most resistant clinical strains in our study, Streptomyces sp. TR1341, originated from a patient with multiorgan tuberculosis, relapsing respiratory infections and chronic obstructive pulmonary disease with a long-term and repeated antibiotic therapy6. This phenotype was supported by genomic analysis, which revealed the presence of 41 known resistance models in its genome15.
Even though non-wild type strains were found in clinical isolates of cluster C, there is no obvious shift in susceptibility category within strains of same phylotype. The ZD value of the only one non-wild type isolate of cluster C that changed susceptibility category compared to wild type isolates balances at the ZD breakpoint value. Therefore, our data suggest a rather species-specific susceptibility profile of Streptomyces. To confirm our findings, we compared the antibiograms of the cluster C strains with those presented in the only study on clinical isolates of S. albidoflavus (Spain) in the literature to date14. All our isolates from cluster C were resistant to ERY and SXT, as reflected also in a low COWT value in case of ERY (COWT for SXT was not calculated since all strains lacked an inhibition zone). Contrary, only 24% of S. albidoflavus isolates from Spain were resistant to ERY. This discrepancy suggests local adaptation of the cluster C species to unique selection pressures in different regions, including differences in agriculture, industry, lifestyle, and also antibiotic and other drug policy (higher consumption of SXT and macrolides in Czech Republic compared to Spain)67,68. Spontaneous mutations conferring ERY-resistance under selection pressure have already been demonstrated in the model actinomycetes S. coelicolor and S. lividans69 and are associated with point mutations in rrnA-23S rRNA and rrnC-23S rRNA70. Since SXT resistance determinants are located on mobile elements such as small plasmids and gene cassettes71, horizontal gene transfer under appropriate conditions is a possibility, although it has not yet been documented for Streptomyces.
In conclusion, we proved a generally high suitability and accuracy of the disk diffusion method for the AST of Streptomyces spp. by correlation with the gold-standard microdilution broth method for 9 antibiotics (SXT remains the questionable due to unresolved ambiguity in cluster D). This led to the determination of DD susceptibility breakpoints derived from MIC breakpoints for Streptomyces—related organisms. To the best of our knowledge, these are the most valid DD breakpoints for Streptomyces reported to date. Tentative breakpoints have been proposed for 10 additional antibiotics, however, these breakpoints were designed primarily for the purpose of this study. Further analyses, such as correlation analyses, are recommended. All tested clinical isolates were susceptible to AKN, GEN, VAN and LIZ which is in agreement with literature, therefore these antibiotics can be chosen as empiric treatment for Streptomyces-associated infections. A low percentage of resistant isolates (˂ 10%) was found in our study for tetracyclines, CLR, CIP and AMC, however, data for CIP and AMC susceptibility differs in literature (Supplementary Table 2). In contrast, Streptomyces are intrinsically resistant to penicillin, and have a high percentage of resistance to cephalosporins. Other antibiograms (ERY and SXT) appear to be regionally driven, rather than species-specific and thus AST must be performed prior therapy. The treatment with ERY and SXT associates with a high risk of failure due to acquired resistance and should be reconsidered. Our study also emphasizes that Streptomyces are emerging in clinical practice, although still largely neglected, and points out the importance of optimizing techniques for selective isolation from clinical specimens. As awareness of streptomycetes infections in humans has increased, it is desirable to continue investigating their virulence factors and clinical relevance.
The datasets used and/or analysed during the current study available from the corresponding author on reasonable request.
Chander, J., Singla, N. & Handa, U. Human cervicofacial mycetoma caused by Streptomyces griseus: First case report. J. Microbiol. Immunol. Infect. 48, 703–705 (2015).
Borelli, D. & Middelveen, M. Actinomycetoma Caused by Streptomyces somaliensis. Arch. Dermatol. 122, 1097–1098 (1986).
Chaudhuri, B. N., Maiti, P. K. & Sil, J. Antibiotic sensitivity patterns of actinomycetes isolated from patients of actinomycetoma. Indian J. Med. Res. 105, 162–166 (1997).
Quintana, E. T. et al. Streptomyces sudanensis sp. nov., a new pathogen isolated from patients with actinomycetoma. Antonie Van Leeuwenhoek 93, 305–313 (2008).
Joseph, N. M., Harish, B. N., Sistla, S., Thappa, D. M. & Parija, S. C. Streptomyces bacteremia in a patient with actinomycotic mycetoma. J. Infect. Dev. Ctries. 4, 249–252 (2010).
Herbrík, A. et al. A human lung-associated Streptomyces sp TR1341 produces various secondary metabolites responsible for virulence, cytotoxicity and codulation of immune response. Front. Microbiol. 10, 1–17 (2020).
Bai, M. et al. Streptomyces pneumonia in an immunocompetent adult—A rare isolate. Adv. Respir. Med. 89, 68–71 (2021).
Raymond, F. et al. The initial state of the human gut microbiome determines its reshaping by antibiotics. ISME J. 10, 707–720 (2016).
Collado, M. C., Rautava, S., Aakko, J., Isolauri, E. & Salminen, S. Human gut colonisation may be initiated in utero by distinct microbial communities in the placenta and amniotic fluid. Sci. Rep. 6, 1–13 (2016).
Huang, Y. J. et al. The airway microbiome in patients with severe asthma: Associations with disease features and severity. J. Allergy Clin. Immunol. 136, 874–884 (2015).
Wu, X. et al. 16S rDNA analysis of periodontal plaque in chronic obstructive pulmonary disease and periodontitis patients. J. Oral Microbiol. 9, 1 (2017).
McNeil, M. M., Brown, J. M., Jarvis, W. R. & Ajello, L. Comparison of species ditribution and antimicrobial susceptibility of aerobic actinomycetes from clinical specimens. Rev. Infect. Dis. 12, 778–783 (1990).
Rose, C. E., Brown, J. M. & Fisher, J. F. Brain abscess caused by Streptomyces infection following penetration trauma: Case report and results of susceptibility analysis of 92 isolates of Streptomyces species submitted to the CDC from 2000 to 2004. J. Clin. Microbiol. 46, 821–823 (2008).
Sáez-Nieto, J. A. et al. Identification and antimicrobial susceptibility of Streptomyces and other unusual Actinobacteria clinical isolates in Spain. New Microbes New Infect. 44, 100946 (2021).
Lara, A. C. et al. The genome analysis of the human lung-associated Streptomyces sp. TR1341 revealed the presence of beneficial genes for opportunistic colonization of human tissues. Microorganisms 9, 1547 (2021).
Rahdar, H. A. et al. Molecular identification and antibiotic resistance pattern of actinomycetes isolates among immunocompromised patients in Iran, emerging of new infections. Sci. Rep. 11, 1–9 (2021).
Hamid, M. E. Variable antibiotic susceptibility patterns among Streptomyces species causing actinomycetoma in man and animals. Ann. Clin. Microbiol. Antimicrob. 10, 1–5 (2011).
Hoza, A. S., Mfinanga, S. G. S., Moser, I. & König, B. Isolation, biochemical and molecular identification of Nocardia species among TB suspects in northeastern, Tanzania; A forgotten or neglected threat?. BMC Infect. Dis. 17, 1–9 (2017).
Ai, L. et al. Chronic suppurative otitis media due to Streptomyces cacaoi, the second case report in human infection. BMC Infect. Dis. 20, 10–13 (2020).
Chinen, J. & Shearer, W. T. Secondary immunodeficiencies, including HIV infection. J. Allergy Clin. Immunol. 125, S195-203 (2010).
Murray, P. R., Heeren, R. & Niles, A. C. Effect of decontamination procedures on recovery of Nocardia spp. J. Clin. Microbiol. 25, 2010–2011 (1987).
Srivastava, S., Chapagain, M. & Gumbo, T. Effect of specimen processing, growth supplement, and different metabolic population on Mycobacterium tuberculosis laboratory diagnosis. PLoS ONE 15, 1–7 (2020).
Mtafya, B. et al. Molecular bacterial load assay concurs withculture on NaOH-induced loss of Mycobacterium tuberculosis viability. J. Clin. Microbiol. 57, 1 (2019).
Scharfen, J. et al. Filamentous ‘contaminants’ in the mycobacteriology laboratory; their culture, identification and clinical significance. Klin. Mikrobiol. Infekc. Lek. 16, 48–57 (2010).
Parte, A. C., Carbasse, J. S., Meier-Kolthoff, J. P., Reimer, L. C. & Göker, M. List of prokaryotic names with standing in nomenclature (LPSN) moves to the DSMZ. Int. J. Syst. Evol. Microbiol. 70, 5607–5612 (2020).
Ghanem, G., Adachi, J., Han, X.-Y. & Raad, I. Central venous catheter-related Streptomyces septic thrombosis. Infect. Control Hosp. Epidemiol. 28, 599–601 (2007).
Kapadia, M., Rolston, K. V. I. & Han, X. Y. Invasive Streptomyces infections: Six cases and literature review. Am. J. Clin. Pathol. 127, 619–624 (2007).
Pellegrini, G. J. et al. Scalp abscess due to Streptomyces cacaoi subsp. cacaoi, first report in a human infection. J. Clin. Microbiol. 50, 1484–1486 (2012).
Yacoub, A. T., Velez, A. P., Khwaja, S. I., Sandin, R. L. & Greene, J. Streptomyces pneumonia in an immunocompromised patient: A case report and a review of literature. Infect. Dis. Clin. Pract. 22, 2–5 (2014).
Kofteridis, D. P. et al. Streptomyces pneumonia in an immunocompetent patient: A case report and literature review. Diagn. Microbiol. Infect. Dis. 59, 459–462 (2007).
Ariza-Prota, M. A. et al. Community-acquired bacteremic Streptomyces atratus pneumonia in an immunocompetent adult: A case report. J. Med. Case Rep. 9, 9–12 (2015).
Manteca, A. et al. A rare case of lung coinfection by Streptomyces cinereoruber and Haemophilus influenzae in a patient with severe chronic obstructive pulmonary disease: characterization at species level using molecular techniques. Diagn. Microbiol. Infect. Dis. 60, 307–311 (2008).
Martín, M. C., Manteca, A., Castillo, M. L., Vázquez, F. & Méndez, F. J. Streptomyces albus isolated from a human actinomycetoma and characterized by molecular techniques. J. Clin. Microbiol. 42, 5957–5960 (2004).
Datta, P., Arora, S., Jain, R., Chander, J. & Van De Sande, W. Secondary peritonitis caused by Streptomyces viridis. J. Clin. Microbiol. 50, 1813–1814 (2012).
CLSI. Performance standards for antimicrobial susceptibility testing. 30th Ed. CLSI guidlines M100 http://em100.edaptivedocs.net/GetDoc.aspx?doc=CLSI M100 ED31:2021&scope=user (2020).
EUCAST. Harmonizing of breakpoints for existing antimicrobial agents. EUCAST standard operation procedure www.eucast.org (2019).
Kieser, T., Bibb, M. J., Buttner, M., Chater, K. F. & Hopwood, D. Growth and preservation of Streptomyces. Pract. Streptomyces Genet. 43–62 (2000).
Rashad, F. M., Fathy, H. M., El-Zayat, A. S. & Elghonaimy, A. M. Isolation and characterization of multifunctional Streptomyces species with antimicrobial, nematicidal and phytohormone activities from marine environments in Egypt. Microbiol. Res. 175, 34–47 (2015).
Zothanpuia, A. K. P., Yadav, M. K. & Singh, B. P. In vitro evaluation of antimicrobial activities and antibiotic susceptibility profiling of culturable actinobacteria from fresh water streams. Indian J. Exp. Biol. 56, 665–673 (2018).
Zothanpuia, A. K. P. & Singh, B. P. Molecular characterization of actinomycetes isolated from Tuichang river and their biosynthetic potential. Sci. Vis. 15, 136–144 (2015).
Petříčková, K. et al. Evolution of cyclizing 5-aminolevulinate synthases in the biosynthesis of actinomycete secondary metabolites: Outcomes for genetic screening techniques. Front. Microbiol. 6, 1–15 (2015).
Altschul, S. F., Gish, W., Miller, W., Myers, E. W. & Lipman, D. J. Basic local alignment search tool. J. Mol. Biol. 215, 403–410 (1990).
Labeda, D. P. et al. Phylogenetic study of the species within the family Streptomycetaceae. Antonie Van Leeuwenhoek 101, 73–104 (2012).
Shirling, E. B. & Gottlieb, D. Methods for characterization of Streptomyces species. Int. J. Syst. Evol. Microbiol. 16, 313–340 (1966).
CLSI. Susceptibility testing of Mycobacteria, and other aerobic Actinomycetes. 2nd edn. CLSI guidlines M24 (2011).
CLSI. Development of in vitro susceptibility testing criteria and quality control parameters. 2nd Ed. CLSI guidlines M23 (2001).
Kronvall, G. & Smith, P. Normalized resistance interpretation, the NRI method: Review of NRI disc test applications and guide to calculations. APMIS 124, 1023–1030 (2016).
Nasher, M. A., Hay, R. J., Mahgoub, E. S. & Gumaa, S. A. In vitro studies of antibiotic sensitivities of Streptomyces somaliensis a cause of human actinomycetoma. Trans. R. Soc. Trop. Med. Hyg. 83, 265–268 (1989).
Moss, W. J., Sager, J. A., Dick, J. D. & Ruff, A. Streptomyces bikiniensis bacteremia. Emerg. Infect. Dis. 9, 273–274 (2003).
Siddiqui, S. et al. Fulminant mulch pneumonitis: An emergency presentation of chronic granulomatous disease. Clin. Infect. Dis. 45, 673–681 (2007).
Riviere, E. et al. Pulmonary treptomyces infection in patient with sarcoidosis, France, 2012. Emerg. Infect. Dis. 18, 1907–1909 (2012).
Kagen, S. L., Fink, J. N., Schlueter, D. P., Kurup, V. P. & Fruchtman, R. B. Streptomyces albus: A new cause of hypersensitivity pneumonitis. J. Allergy Clin. Immunol. 68, 295–299 (1981).
Kawakami, H. et al. Case of keratitis caused by Streptomyces thermocarboxydus. J. Infect. Chemother. 20, 57–60 (2014).
Anderson, A. S. & Wellington, E. M. H. The taxonomy of Streptomyces and related genera. Int. J. Syst. Evol. Microbiol. 51, 797–814 (2001).
Ogawara, H. Self-resistance in Streptomyces, with special reference to β-lactam antibiotics. Molecules 21, 1–30 (2016).
Welsh, O., Al-Abdely, H. M., Salinas-Carmona, M. C. & Fahal, A. H. Mycetoma medical therapy. PLoS Negl. Trop. Dis. 8, 1 (2014).
Williams, S. T. Sensitivity of streptomycetes. J. Gen. Microbiol. 46, 151–160 (1967).
Cox, H. & Ford, N. Linezolid for the treatment of complicated drug-resistant tuberculosis: A systematic review and meta-analysis. Int. J. Tuberc. Lung Dis. 16, 447–454 (2012).
Myneedu, V. P. et al. First and second line drug resistance among treatment naïve pulmonary tuberculosis patients in a district under Revised National Tuberculosis Control Programme (RNTCP) in New Delhi. J. Epidemiol. Glob. Health 5, 365–373 (2015).
Beneš, J. Antibiotika: systematika, vlastnosti, použití. (Grada Publishing, 2018).
Xie, J., Talaska, A. E. & Schacht, J. New developments in aminoglycoside therapy and ototoxicity. Hear. Res. 281, 28–37 (2011).
Krause, K. M., Serio, A. W., Kane, T. R. & Connolly, L. E. Aminoglycosides: An overview. Cold Spring Harb. Perspect Med. 6, a027029 (2016).
Bébrová, E. et al. Doporučený postup pro antibiotickou léčbu komunitních respiračních infekcí v primární péči. Prakt. Lék. 83, 502–515. www.cls.cz/dokumenty/Doporuceny_postup_ATB_lecba.doc (2003).
Lee, L. F., Chen, Y. J., Kirby, R., Chen, C. & Chen, C. W. A multidrug efflux system is involved in colony growth in Streptomyces lividans. Microbiology 153, 924–934 (2007).
Hong, H. J. et al. Characterization of an inducible vancomycin resistance system in Streptomyces coelicolor reveals a novel gene (vanK) required for drug resistance. Mol. Microbiol. 52, 1107–1121 (2004).
Lee, L.-F., Huang, Y.-J. & Chen, C. W. Repressed multidrug resistance genes in Streptomyces lividans. Arch. Microbiol. 180, 176–184 (2003).
Versporten, A. et al. Consumption of tetracyclines, sulphonamides and trimethoprim, and other antibacterials in the community, European Union/European Economic Area, 1997–2017. J. Antimicrob. Chemother. 76, 45–59 (2021).
Adriaenssens, N. et al. Consumption of macrolides, lincosamides and streptogramins in the community, European Union/European Economic Area, 1997–2017. J. Antimicrob. Chemother. 76, 30–36 (2021).
Imai, Y., Fujiwara, T., Ochi, K. & Hosaka, T. Development of the ability to produce secondary metabolites in Streptomyces through the acquisition of erythromycin resistance. J. Antibiot. (Tokyo) 65, 323–326 (2012).
Hoshino, K. et al. A putative mechanism underlying secondary metabolite overproduction by Streptomyces strains with a 23S rRNA mutation conferring erythromycin resistance. Appl. Microbiol. Biotechnol. 104, 2193–2203 (2020).
Sköld, O. Resistance to trimethoprim and sulfonamides. Vet. Res. 32, 261–273 (2001).
This study was funded by the project of the Ministry of Healthcare of the Czech Republic (No. 17-30091A) and the Research Programme of the Academy of Sciences of the Czech Republic Strategy AV21 “Diversity of life and health of ecosystems” and “Land conservation and restoration”. Special thanks to MVDr. Petr Ježek from Příbram Regional Hospital for providing clinical isolates. The authors thank Václav Krištůfek, Martina Petrlíková, Petra Beníšková, Nikola Fuková and František Lorenc for technical support.
The authors declare no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Kotrbová, L., Lara, A.C., Corretto, E. et al. Evaluation and comparison of antibiotic susceptibility profiles of Streptomyces spp. from clinical specimens revealed common and region-dependent resistance patterns. Sci Rep 12, 9353 (2022). https://doi.org/10.1038/s41598-022-13094-4